NRx Pharmaceuticals Announces FDA Found No Major Deficiencies In Its First-Cycle Review Of ANDA For Its Preservative-Free Ketamine
No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufacturing and Controls, or other drug-related review matters. No new clinical, safety, efficacy, or drug-related data are
NRx's ketamine medicine passed its first FDA checkup with no big problems found. This means the company is moving forward on track, so watch if they announce approval soon—that would show their drug is getting closer to helping patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.